Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
2016 · New England Journal of Medicine · 1,957 citations
https://doi.org/10.1056/nejmoa1609709
W
Wolfgang Janni
Universität Ulm(DE)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
954
Papers
29.7K
Citations
69
h-index
320
i10-index
Wolfgang Janni is an academic researcher from Universität Ulm. The author has contributed to research in topics: Breast Cancer Treatment Studies & Advanced Breast Cancer Therapies & HER2/EGFR in Cancer Research. The author has an h-index of 69, co-authored 811 publications.
ORCID: 0000-0001-5911-2400Papers by this author
worksAssociation analysis identifies 65 new breast cancer risk loci
2017 · Nature · 1,557 citations
https://doi.org/10.1038/nature24284
A Pooled Analysis of Bone Marrow Micrometastasis in Breast Cancer
2005 · New England Journal of Medicine · 1,375 citations
https://doi.org/10.1056/nejmoa050434
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes
2018 · The American Journal of Human Genetics · 1,152 citations
https://doi.org/10.1016/j.ajhg.2018.11.002
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
2023 · Annals of Oncology · 724 citations
https://doi.org/10.1016/j.annonc.2023.11.016
Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses
2020 · Nature Genetics · 551 citations
https://doi.org/10.1038/s41588-020-0609-2
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat